Investment Thesis
Vir Biotechnology exhibits critical operational deficiencies with negative revenue, -$132M operating cash burn, and no clear path to profitability despite an adequate cash reserve of $274M. While the balance sheet is fortress-like with zero debt and strong liquidity, the unsustainable cash burn rate (approximately $132M quarterly) provides only 2 years of runway, and deteriorating fundamentals outweigh balance sheet strength. The negative revenue figure raises data quality concerns but the underlying operational losses and negative cash conversion are authentic warning signs.
Strengths
- Strong balance sheet with $274.2M cash and zero long-term debt
- Excellent liquidity position (7.11x current and quick ratios)
- Substantial asset base ($1.0B) provides operational foundation
- Improving loss trends year-over-year (net income improved 16.1%, EPS improved 17.5%)
Risks
- Negative revenue (-$29.0K) indicates potential data quality issues or fundamental business problems
- Operating cash burn of -$132.4M quarterly is unsustainable without revenue generation or capital raise
- No visibility into product pipeline success probability or time to profitability from SEC data alone
- Negative ROE (-15.5%) and ROA (-12.3%) confirm shareholder value destruction
- Cash runway of ~2 years at current burn rate requires successful pipeline advancement
Key Metrics to Watch
- Quarterly revenue trends and achievement of commercial milestones
- Operating cash flow burn rate and runway duration
- Progress on pipeline programs and clinical trial advancement
- Capital raise activity and dilution impact on equity
Financial Metrics
Revenue
-29.0K
Net Income
-125.7M
EPS (Diluted)
$-0.85
Free Cash Flow
-132.8M
Total Assets
1.0B
Cash
274.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
456,172.4%
Net Margin
433,431.0%
ROE
-15.5%
ROA
-12.3%
FCF Margin
457,848.3%
Balance Sheet & Liquidity
Current Ratio
7.11x
Quick Ratio
7.11x
Debt/Equity
0.00x
Debt/Assets
20.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T12:59:26.032110 |
Data as of: 2026-03-31 |
Powered by Claude AI